Prophylaxis for Human Immunodeficiency Virus–Related Pneumocystis carinii Pneumonia
Authors:
- Sue J. GoldieSGSue J. Goldie
- Jonathan E. KaplanJKJonathan E. Kaplan
- Elena LosinaELElena Losina
- Milton C. WeinsteinMWMilton C. Weinstein
- A. David PaltielAPA. David Paltiel
- George R. SeageGSGeorge R. Seage
- Donald E. CravenDCDonald E. Craven
- April D. KimmelAKApril D. Kimmel
- Hong ZhangHZHong Zhang
- Calvin J. CohenCCCalvin J. Cohen
- Kenneth A. FreedbergKFKenneth A. Freedberg
Open Access
- 22 April 2002
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 162 (8) , 921-928
Abstract
PNEUMOCYSTIS CARINII pneumonia (PCP) is the most common serious opportunistic infection among patients infected with human immunodeficiency virus (HIV) in the United States.1-3 Initiating PCP prophylaxis at a CD4 cell count less than 200/µL has been the standard of care for the past decade.4,5 In the past few years, however, there has been a dramatic reduction in the rates of opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy (HAART), prompting reassessment of the role of prophylaxis.6-24 Several recent publications25-28 suggest a convergence of opinion in favor of discontinuing PCP prophylaxis in patients whose CD4 cell counts have increased to greater than 200/µL with HAART.Keywords
This publication has 1 reference indexed in Scilit:
- Updates of Cost of Illness and Quality of Life Estimates for Use in Economic Evaluations of HIV Prevention ProgramsJAIDS Journal of Acquired Immune Deficiency Syndromes, 1997